Guadix Scientist Wins L’Oréal‑UNESCO Prize

Genome editing is the broad idea here — tools that rewrite DNA so a harmful mutation stops causing disease. The promise has been obvious for years. The hard part is precision. Cutting DNA is one thing; fixing the exact broken sequence, in the right place, without creating a new problem, is much harder. That is why Ylenia Jabalera’s new prize matters. On April 29, 2026, the Spanish edition of the L’Oréal‑UNESCO For Women in Science awards gave her one of five research prizes for a project aimed at correcting genetic mutations that still have no treatment. (granadahoy.com) ### Who is Ylenia Jabalera? Jabalera is a scientist from Guadix, in Granada province, and she now leads research at CIC bioGUNE in the Basque Country as an Ikerbasque fellow and emerging scientist. Her lab works on genome engineering — basically, how to build better molecular tools for rewriting DNA. She trained in Granada and has worked across Spain and Europe before setting up her own line of research. (ikerbasque.net) ### What exactly did she win? This was not the global L’Oréal‑UNESCO lifetime-style award that honors one scientist per world region. It was the Spain research-prize program, which in 2026 gave five awards tied to projects led by young women scientists. Each prize is worth €15,000 and is awarded to the research center supporting the scientist’s 2026 project. That distinction matters because it means the money is(ikerbasque.net)lts. (granadahoy.com) ### What is her project trying to do? The short version is simple: build tools that can correct mutations behind genetic diseases that currently cannot be treated. But the interesting part is how. Jabalera’s research focuses on CRISPR systems and mobile genetic elements called transposons. Instead of relying only on the now-familiar “genetic scissors” model — cu(granadahoy.com)s. (granadahoy.com) ### Why is precise insertion such a big deal? Because many diseases are not solved by making a cut. You may need to replace a missing sequence, insert a healthy version, or land a change at one exact address in the genome. Think of the difference between deleting a typo and pasting in the right sentence at the right line. Jabalera’s lab is trying to make that second trick more reliable by combining evolutionary analysis, structural biology, and protein engineering. (becarios.fundacionlacaixa.org) ### What has she already shown? She is not starting from zero. Jabalera coauthored a 2024 Nature Biotechnology paper on an ancestral version of Cas12a — a CRISPR-associated enzyme — that expanded target access and substrate recognition for editing and detection. In plain English, that means her work has already helped show that older, reconstructed versions of these molecular machines can do useful things modern tools cannot do as easily. (nature.com) ### Why does this prize matter beyond one résumé line? Money helps, but visibility helps too. The Spain program has been running for 20 years and is built to spotlight women scientists whose work is still in the build phase. That can make it easier to attract collaborators, justify a risky research direction, and turn a promising platform into something funders and institutions take seriously. In genome editing, that middle stage is often where good ideas stall. (infobae.com) ### Why does Guadix show up in the story? Because local science stories usually surface only after someone leaves for a bigger center and wins something national. Jabalera’s prize is a reminder that the pipeline starts far earlier — in provincial cities, public universities, and long training paths that rarely get attention until a major award lands. The Guadix angle is real, but the work itself is now plugged into a much larger European genome-editing ecosystem. (granadahoy.com) ### So what is the bottom line? This is not a cured-disease headline. It is a tools headline. But tools are how this field moves. Jabalera won because her work aims at one of the hardest problems in genetic medicine — making DNA changes that are not just possible, but precise enough to become real therapies. (granadahoy.com)